Neha Vapiwala1, Wei-Ting Hwang2, Carolyn J Kushner1, Mitchell D Schnall3, Gary M Freedman1, Lawrence J Solin4. 1. Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania. 2. Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania. 3. Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania. 4. Department of Radiation Oncology, Albert Einstein Healthcare Network, Philadelphia, Pennsylvania.
Abstract
BACKGROUND: For women undergoing breast conservation therapy (BCT), the added value of breast magnetic resonance imaging (MRI) at the time of initial diagnosis remains controversial. The current study was performed to determine long-term outcomes after BCT for women with and without pretreatment breast MRI. METHODS: Between 1992 and 2001, a total of 755 women with ductal carcinoma in situ or early-stage invasive breast cancer underwent breast-conserving surgery (with axillary lymph node staging for invasive carcinoma) followed by definitive breast radiotherapy. Evaluation at the time of the initial diagnosis included conventional mammography in all subjects and breast MRI in 215 women (28%). Clinical, pathologic, and treatment characteristics were comparable for patients with and without breast MRI. Outcomes were determined using the Kaplan-Meier method and compared using the log-rank method. RESULTS: At a median follow-up of 13.8 years, there were 49 local failures (15 women with and 34 women without breast MRI, respectively). The 15-year local failure rates were 8% for women with and 8% for women without MRI (P = .59). There also were no differences noted between women with and without breast MRI with regard to 15-year rates of overall survival (77% vs 71%; P = .24), freedom from distant metastases (86% vs 90%; P = .08), and contralateral breast cancer (10% vs 8%; P = .10). Multivariate analysis demonstrated no significant impact of breast MRI on local failure (P = .96). CONCLUSIONS: Breast MRI during the initial evaluation for BCT appears to have no significant impact on 15-year rates for local control, overall survival, freedom from distant metastases, or contralateral breast cancer. The routine use of pretreatment breast MRI is not indicated for patients undergoing BCT. Cancer 2017;123:1324-1332.
BACKGROUND: For women undergoing breast conservation therapy (BCT), the added value of breast magnetic resonance imaging (MRI) at the time of initial diagnosis remains controversial. The current study was performed to determine long-term outcomes after BCT for women with and without pretreatment breast MRI. METHODS: Between 1992 and 2001, a total of 755 women with ductal carcinoma in situ or early-stage invasive breast cancer underwent breast-conserving surgery (with axillary lymph node staging for invasive carcinoma) followed by definitive breast radiotherapy. Evaluation at the time of the initial diagnosis included conventional mammography in all subjects and breast MRI in 215 women (28%). Clinical, pathologic, and treatment characteristics were comparable for patients with and without breast MRI. Outcomes were determined using the Kaplan-Meier method and compared using the log-rank method. RESULTS: At a median follow-up of 13.8 years, there were 49 local failures (15 women with and 34 women without breast MRI, respectively). The 15-year local failure rates were 8% for women with and 8% for women without MRI (P = .59). There also were no differences noted between women with and without breast MRI with regard to 15-year rates of overall survival (77% vs 71%; P = .24), freedom from distant metastases (86% vs 90%; P = .08), and contralateral breast cancer (10% vs 8%; P = .10). Multivariate analysis demonstrated no significant impact of breast MRI on local failure (P = .96). CONCLUSIONS: Breast MRI during the initial evaluation for BCT appears to have no significant impact on 15-year rates for local control, overall survival, freedom from distant metastases, or contralateral breast cancer. The routine use of pretreatment breast MRI is not indicated for patients undergoing BCT. Cancer 2017;123:1324-1332.
Authors: Laura Burkbauer; Macy Goldbach; Daniel I Hoffman; Andreas Giannakou; Rachel Dultz; Ari D Brooks; Dahlia M Sataloff; Luke Keele; Julia Tchou Journal: Ann Surg Oncol Date: 2022-03-18 Impact factor: 5.344
Authors: Amy J Lilly; Meredith Johnson; Cherie M Kuzmiak; David W Ollila; Siobhan M O'Connor; Johann D Hertel; Benjamin C Calhoun Journal: Ann Diagn Pathol Date: 2020-07-03 Impact factor: 2.090
Authors: Henry M Kuerer; Benjamin D Smith; Mariana Chavez-MacGregor; Constance Albarracin; Carlos H Barcenas; Lumarie Santiago; Mary E Edgerton; Gaiane M Rauch; Sharon H Giordano; Aysegul Sahin; Savitri Krishnamurthy; Wendy Woodward; Debasish Tripathy; Wei T Yang; Kelly K Hunt Journal: J Cancer Date: 2017-08-22 Impact factor: 4.207
Authors: Xiao Xu; Pamela R Soulos; Jeph Herrin; Shi-Yi Wang; Craig Evan Pollack; Brigid K Killelea; Howard P Forman; Cary P Gross Journal: PLoS One Date: 2022-03-15 Impact factor: 3.240
Authors: T J A van Nijnatten; L P T van Tiel; A C Voogd; C G M Groothuis-Oudshoorn; S Siesling; M B I Lobbes Journal: Breast Cancer Res Treat Date: 2020-09-15 Impact factor: 4.872